Weight loss trajectory was still accelerating Phase 1 (oral): 10.4-13.1% weight loss at 12 weeks depending on dosing regimen vs 1.2% placebo Phase 2 (T2D): SC amycretin showed up to 14.5% weight loss and HbA1c reductions up to 1.8% at 36 weeks
A clinical conversation should clarify your expectations for semaglutide's effects
The main neurocognitive disorders in NDD (AD, PD, etc.), conditions related to alcohol and substance abuse, stroke, traumatic brain injury, and depressive disorders are the closest therapeutic targets
No more afternoon energy crashes that send you searching for sugar or caffeine
In a meta-analysis of 37 studies, berberine reduced fasting plasma glucose (aka blood sugar) by an average of 0.82 mmol/L (14.77 mg/dL)
Standard blood workincluding complete blood counts, comprehensive metabolic panels, lipid profiles, or HbA1c measurementsassesses various health markers and metabolic parameters but does not identify or quantify GLP-1 medications in the bloodstream